Phase Forward Central Coding™ First to Achieve Uppsala Monitoring Center Certification

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its Central Coding™ application has become the first product to achieve certification by the Uppsala Monitoring Center (UMC). Launched today (“Uppsala Monitoring Centre Launches Software Certification Program for WHO Drug Dictionary Enhanced”), UMC’s new certification is designed to help software developers quickly and easily integrate the WHO Drug Dictionary Enhanced. The WHO Drug Dictionary Enhanced is the world’s most comprehensive dictionary of medicinal product information and the de facto standard for coding concomitant medication in clinical trials and adverse event reporting.

Optimized to work with InForm™ Global Trial Management (GTM) and other Phase Forward solutions, Central Coding is a configurable, multilingual, Web-based coding and dictionary management application designed to automate the coding process and minimize the manual effort required to code verbatim terms. The Central Coding application successfully passed the 24 use cases and associated acceptance criteria included in the UMC certification process, designed to indicate that vendor implementation processes are accurate.

The certification announced today also offers software developers free training and a software development kit, including documentation and example programs. UMC is demonstrating the features of the new certification program at the Drug Information Association’s 46th Annual Meeting in Washington, D.C., which began yesterday and runs through this Thursday, June 17.

“UMC certification is a rigorous undertaking, and Phase Forward completed the process impressively, clearly benefiting from their WHO Dictionary integration expertise and experience with the Central Coding product,” said Ola Strandberg, Vendor Liaison Officer at UMC. “Having achieved certification, Phase Forward Central Coding offers users a product that has demonstrated full utilization of the Dictionary’s constantly evolving feature set.”

“UMC has devised a useful certification process to help organizations like ours achieve integration with the WHO Drug Dictionary Enhanced,” said Martin Young, Phase Forward Senior Vice President, Integration and Product Strategy. “In working closely together on this certification we had ample opportunity to observe the commitment of the UMC team. We congratulate them on the formal launch today, and are proud to concurrently announce our position as the first vendor to achieve the certification.”

More information about the Software Certification Program is available at http://www.umc-products.com/certification.

About the Uppsala Monitoring Centre

The Uppsala Monitoring Centre (UMC) provides tools and resources to enhance clinical trials and drug safety operations, ranging from international monitoring of drug safety data to lexicon products and advanced tools for data analysis. Our main products are:

• The WHO Drug Dictionary Enhanced is the world’s most comprehensive dictionary of medicinal product information and de-facto standard for coding concomitant medication in clinical trials and adverse event reporting.
• VigiBase™ – the WHO adverse drug reaction database, which is the world’s largest and most comprehensive resource of international drug safety data.

As a centre of scientific excellence, UMC has extensive experience of database administration and data mining complex sets of clinical data. To advance this work, UMC has developed a range of products and techniques for companies and organizations working with life sciences.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the continued interoperability and integration of Phase Forward's products with third-party offerings, the benefits to customers from such interoperability and integration, the continued ability of Phase Forward’s products to meet the certification requirements of third parties and the performance and acceptance of Phase Forward’s products. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, Phase Forward's inability to convince current and potential customers to order its products and services, the failure of customers to realize benefits from the interoperability and integration of Phase Forward’s and third-party offerings, changes in the technical specifications of Phase Forward’s products or third-party offerings and the ability of Phase Forward to maintain the certification requirements of third parties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.